The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis

References

• Weber, C.R., Turner, J.R. Inflammatory bowel disease: is it really just another break in the wall? Gut 2007, 56, 6–8.
   PubMed Web of Science ®Google Scholar
• Hollander, D. Crohn’s disease—a permeability disorder of the tight junction? Gut 1988, 29, 1621–1624.
   PubMed Web of Science ®Google Scholar
• Karlinger, K., Györke, T., Makö, E., Mester, A., Tarján, Z. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 2000, 35, 154–167.
   PubMed Web of Science ®Google Scholar
• Koutroubakis, I., Manousos, O.N., Meuwissen, S.G., Pena, A.S. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 1996, 43, 381–393.
   PubMedGoogle Scholar
• Bamias, G., Cominelli, F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol 2007, 23, 365–369.
   PubMed Web of Science ®Google Scholar
• Shih, D.Q., Targan, S.R. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008, 14, 390–400.
   PubMed Web of Science ®Google Scholar
• Rogler, G., Andus, T. Cytokines in inflammatory bowel disease. World J Surg 1998, 22, 382–389.
   PubMed Web of Science ®Google Scholar
• Kolls, J.K., Lindén, A. Interleukin-17 family members and inflammation. Immunity 2004, 21, 467–476.
   PubMed Web of Science ®Google Scholar
• Gross, V., Andus, T., Caesar, I., Roth, M., Schölmerich, J. Evidence for continuous stimulation of interleukin-6 production in Crohn’s disease. Gastroenterology 1992, 102, 514–519.
   PubMed Web of Science ®Google Scholar
• Plevy, S.E., Landers, C.J., Prehn, J., Carramanzana, N.M., Deem, R.L., Shealy, D., Targan, S.R. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol 1997, 159, 6276–6282.
   PubMed Web of Science ®Google Scholar
• Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., McKenzie, B., Kleinschek, M.A., Owyang, A., Mattson, J., Blumenschein, W., Murphy, E., Sathe, M., Cua, D.J., Kastelein, R.A., Rennick, D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116, 1310–1316.
   PubMed Web of Science ®Google Scholar
• Sandborn, W.J., Targan, S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002, 122, 1592–1608.
   PubMed Web of Science ®Google Scholar
• Van Deventer, S.J. Immunotherapy of Crohn’s disease. Scand J Immunol 2000, 51, 18–22.
   PubMedGoogle Scholar
• Targan, S.R., Feagan, B.G., Fedorak, R.N., Lashner, B.A., Panaccione, R., Present, D.H., Spehlmann, M.E., Rutgeerts, P.J., Tulassay, Z., Volfova, M., Wolf, D.C., Hernandez, C., Bornstein, J., Sandborn, W.J.; International Efficacy of Natalizumab in Crohn’s Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology 2007, 132, 1672–1683.
   PubMed Web of Science ®Google Scholar
• Powrie, F., Carlino, J., Leach, M.W., Mauze, S., Coffman, R.L. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 1996, 183, 2669–2674.
   PubMed Web of Science ®Google Scholar
• Corsini, A., Maggi, F.M., Catapano, A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995, 31, 9–27.
   PubMed Web of Science ®Google Scholar
• Kitamoto, S., Egashira, K. [Anti-inflammatory effect of HMG-CoA reductase inhibitors]. Nippon Rinsho 2004, 62, 172–179.
   PubMedGoogle Scholar
• Stumpf, C., Petzi, S., Seybold, K., Wasmeier, G., Arnold, M., Raaz, D., Yilmaz, A., Daniel, W.G., Garlichs, C.D. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clin Sci 2009, 116, 45–52.
   Google Scholar
• Montecucco, F., Mach, F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol 2009, 31, 127–142.
   PubMedGoogle Scholar
• Kwak, B., Mulhaupt, F., Myit, S., Mach, F. Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6, 1399–1402.
   PubMed Web of Science ®Google Scholar
• Weitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., Hommel, U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001, 7, 687–692.
   PubMed Web of Science ®Google Scholar
• Aharoni, R., Kayhan, B., Arnon, R. Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis. Inflamm Bowel Dis 2005, 11, 106–115.
   PubMedGoogle Scholar
• Reuter, B.K., Asfaha, S., Buret, A., Sharkey, K.A., Wallace, J.L. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996, 98, 2076–2085.
   PubMed Web of Science ®Google Scholar
• Aharoni, R., Kayhan, B., Brenner, O., Domev, H., Labunskay, G., Arnon, R. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. J Pharmacol Exp Ther 2006, 318, 68–78.
   PubMedGoogle Scholar
• Mayer, L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 2010, 45, 9–16.
   PubMed Web of Science ®Google Scholar
• Levine, A. Pediatric inflammatory bowel disease: is it different? Dig Dis 2009, 27, 212–214.
   PubMed Web of Science ®Google Scholar
• Kamm, C.P., Mattle, H.P.; SWABIMS Study Group. SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)—rationale, design and methodology. Trials 2009, 10, 115.
   PubMedGoogle Scholar
• Nikitina, N.M., Rebrov, A.P. [The use of atorvastatin in patients with rheumatoid arthritis with hyperlipidemia]. Kardiologiia 2009, 49, 21–26.
   PubMedGoogle Scholar
• Ljuca, F., Gegic, A., Salkic, N.N., Pavlovic-Calic, N. Circulating cytokines reflect mucosal inflammatory status in patients with Crohn’s disease. Dig Dis Sci 2010, 55, 2316–2326.
   PubMedGoogle Scholar
• D’haens, G., Van Deventer, S., Van Hogezand, R., Chalmers, D., Kothe, C., Baert, F., Braakman, T., Schaible, T., Geboes, K., Rutgeerts, P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999, 116, 1029–1034.
   PubMed Web of Science ®Google Scholar
• Rutgeerts, P., D’Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S.B., Present, D.H., Mayer, L., Van Hogezand, R.A., Braakman, T., DeWoody, K.L., Schaible, T.F., Van Deventer, S.J. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999, 117, 761–769.
   PubMed Web of Science ®Google Scholar
• Lee, J.Y., Kim, J.S., Kim, J.M., Kim, N., Jung, H.C., Song, I.S. Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol 2007, 7, 241–248.
   PubMedGoogle Scholar
• Ikeda, M., Takeshima, F., Isomoto, H., Shikuwa, S., Mizuta, Y., Ozono, Y., Kohno, S. Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis. Dig Dis Sci 2008, 53, 1869–1875.
   PubMedGoogle Scholar
• Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J., Gurney, A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278, 1910–1914.
   PubMed Web of Science ®Google Scholar
• Heo, Y.J., Joo, Y.B., Oh, H.J., Park, M.K., Heo, Y.M., Cho, M.L., Kwok, S.K., Ju, J.H., Park, K.S., Cho, S.G., Park, S.H., Kim, H.Y., Min, J.K. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. Immunol Lett 2010, 127, 150–156.
   PubMed Web of Science ®Google Scholar
• Cheng, X., Ding, Y., Xia, C., Tang, T., Yu, X., Xie, J., Liao, M., Yao, R., Chen, Y., Wang, M., Liao, Y.H. Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J Card Fail 2009, 15, 158–162.
   PubMedGoogle Scholar
• Wei, L., Wei-Min, L., Cheng, G., Ning-Ling, S. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J Autoimmun 2005, 25, 258–263.
   PubMedGoogle Scholar